Maze Therapeutics’ (MAZE) “Buy” Rating Reaffirmed at HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $110.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 306.52% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Citigroup assumed coverage on shares of Maze Therapeutics in a report on Wednesday. They issued a “buy” rating and a $50.00 target price on the stock. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Tuesday. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, Wedbush reiterated an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $63.40.

Maze Therapeutics Trading Down 3.7%

MAZE stock traded down $1.03 during midday trading on Thursday, hitting $27.06. The stock had a trading volume of 89,706 shares, compared to its average volume of 658,667. The firm has a market cap of $1.50 billion, a P/E ratio of -10.69 and a beta of 2.17. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics has a 1-year low of $21.95 and a 1-year high of $53.65. The business has a fifty day moving average price of $27.18 and a two-hundred day moving average price of $29.17.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). On average, sell-side analysts predict that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In related news, insider Courtney Phillips sold 2,012 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $52,332.12. Following the sale, the insider owned 7,007 shares in the company, valued at $182,252.07. This represents a 22.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $26.22, for a total transaction of $254,465.10. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 191,459 shares of company stock worth $5,263,539. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in MAZE. Squarepoint Ops LLC raised its holdings in shares of Maze Therapeutics by 42.8% in the 2nd quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock worth $580,000 after acquiring an additional 5,822 shares during the last quarter. Frazier Life Sciences Management L.P. increased its stake in Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after buying an additional 465,641 shares during the last quarter. AXQ Capital LP lifted its position in shares of Maze Therapeutics by 114.1% during the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock worth $453,000 after buying an additional 8,098 shares in the last quarter. Braidwell LP bought a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Maze Therapeutics by 4,054.3% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock worth $529,000 after buying an additional 17,312 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.